Citius Pharmaceuticals
CTXR
56 hedge funds and large institutions have $18.9M invested in Citius Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 16 closing their positions.
1,223% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $108K
35% more capital invested
Capital invested by funds: $14M → $18.9M (+$4.9M)
0.04% less ownership
Funds ownership: 0.42% → 0.38% (-0.04%)
7% less funds holding
Funds holding: 60 → 56 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$155K |
| 2 |
SG Americas Securities
New York
|
+$98.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$51.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$47.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.05M |
| 2 |
Goldman Sachs
New York
|
-$203K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$142K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$133K |
| 5 |
E
Ergoteles
New York
|
-$79K |
CTXR Hedge Fund Activity: Q3 2022 in Review
56 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2022, worth a combined $18.9M — up 35% from $14M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CTXR and 12 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $155K. The largest seller was Millennium Management, cutting an estimated $1.05M.
- 56 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2022, down from 60 in Q2 2022.
- Funds reported $18.9M of Citius Pharmaceuticals stock for Q3 2022, up 35% quarter-over-quarter.
- 12 funds opened new Citius Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of -4 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2022 was GSA Capital Partners, an estimated $155K added.
- The largest Citius Pharmaceuticals seller in Q3 2022 was Millennium Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2022.